Bjornsdottir E, Janson C, Lindberg E, Arnardottir ES, Benediktsdottir B, Garcia-Aymerich J, Carsin AE, Real FG, Toren K, Heinrich J, Nowak D, Sanchez-Ramos JL, Demoly P, Arenas SD, Navarro RC, Schlunssen V, Raherison C, Jarvis DL, Gislason T. Respiratory symptoms are more common among short sleepers independent of obesity. BMJ Open Respir Res. 2017 Aug 30;4(1):e000206. doi: 10.1136/bmjresp-2017-000206
Pajouheshnia R, Peelen LM, Moons KGM, Reitsma JB, Groenwold RHH. Accounting for treatment use when validating a prognostic model: a simulation study. BMC Med Res Methodol. 2017 Jul 14;17(1):103. doi: 10.1186/s12874-017-0375-8
Pajouheshnia R, Pestman WR, Teerenstra S, Groenwold RHH. A computational approach to compare regression modelling strategies in prediction research. BMC Med Res Methodol. 2016 Aug 25;16(1):107. doi: 10.1186/s12874-016-0209-0
Le HV, Poole C, Brookhart MA, Schoenbach VJ, Beach KJ, Layton JB, Stumer T. Effects of aggregation of drug and diagnostic codes on the performance of the high-dimensional propensity score algorithm: an empirical example. BMC Med Res Methodol. 2013 Nov 19;13:142. doi: 10.1186/1471-2288-13-142
Schneeweiss S, Rassen JA, Glynn RJ, Myers J, Daniel GW, Singer J, Solomon DH, Kim SY, Rothman KJ, Avorn J. Supplementing claims data with outpatient laboratory test results to improve confounding adjustment in effectiveness studies of lipid-lowering treatments. BMC Med Res Methodol. 2012 Nov 26;12(11):180.
Gili M, Luciano JV, Bauzá N, Aguado J, Serrano MJ, Armengol S, Roca M. Psychometric properties of the IDS-SR30 for the assessment of depressive symptoms in Spanish population. BMC Med Res Methodol. 2011 Sep;21(11):131.
Mease PJ, Clauw DJ, Christensen R, Crofford LJ, Gendreau RM, Martin SA. Toward development of a fibromyalgia responder index and disease activity score: oMERACT module update. J Rheumatol. 2011 Jul 1;38(7):1487-95.
Luciano JV, Ayuso-Mateos JL, Aguado J, Fernandez A, Serrano-Blanco A, Roca M, Haro JM. The 12-item World Health Organization Disability Assessment Schedule II (WHO-DAS II): a nonparametric item response analysis. BMC Med Res Methodol. 2010 May 20;10(45). doi: 10.1186/1471-2288-10-45.
Choy EH, Arnold LM, Clauw DJ, Crofford LJ, Glass JM, Simon LS, Martin SA, Strand CV, Williams DA, Mease PJ. Content and criterion validity of the preliminary core dataset for clinical trials in fibromyalgia syndrome. J Rheumatol. 2009 Oct 1;36(10):2330-4.
Mease P, Arnold LM, Choy EH, Clauw DJ, Crofford LJ, Glass JM, Martin SA, Morea J, Simon L, Strand CV, Williams DA. Fibromyalgia syndrome module at OMERACT 9: domain construct. J Rheumatol. 2009 Oct 1;36(10):2318-29.
Mease PJ, Russell IJ, Arnold LM, Florian H, Young JP, Martin SA, Sharma U. A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. J Rheumatol. 2008 Mar;35(3):502-14.
Mease P, Arnold LM, Bennett R, Boonen A, Buskila D, Carville S, Chappell A, Choy E, Clauw D, Dadabhoy D, Gendreau M, Goldenberg D, Littlejohn G, Martin SA. OMERACT 8 workshop: fibromyalgia syndrome. J Rheumatol. 2007 Jun;34(6):1415-25.
Neville C, Whalley D, McKenna SP, Le Comte M, Fortin PR. Adaptation and validation of the Rheumatoid Arthritis Quality of Life Scale for use in Canada. J Rheumatol. 2001 Jul 1;28(7):1505-10.
Norton EC, Zarkin GA, Calingaert B, Bradley CJ. The effect of maternal substance abuse on the cost of neonatal care. Inquiry. 1996;33(3):247-57.
Perez-Gutthann S, Petri M, Hochberg MC. Comparison of two methods of classifying patients with systemic lupus erythematosus. J Rheumatol. 1991 Aug 1;18(8):1176-9.